文献速递泌尿男性生殖肿瘤妇科肿瘤消化系统肿瘤

树状大分子纳米颗粒递送卡巴他赛(DEP-卡巴他赛)在晚期实体瘤中的首次人体1/2期试验

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.
PubMed 文献 · Eur J Cancer · 2026-05-22

该1/2期试验评估DEP-卡巴他赛(CTX-SPL9111)在晚期实体瘤中的安全性、耐受性、药代动力学和抗肿瘤活性。MTD和RP2D为20 mg/m2卡巴他赛,未观察到DLT。2期可评估患者ORR为20%,DCR为70.6%,中位PFS和OS分别为3.8和9.0个月。

要点

  • DEP-卡巴他赛的MTD和RP2D为20 mg/m2卡巴他赛,未观察到DLT。
  • 2期可评估患者ORR为20%,DCR为70.6%,中位PFS 3.8个月、OS 9.0个月。
  • 3/4级中性粒细胞减少发生率为22.7%,发热性中性粒细胞减少为1.3%。

核心结论

  • DEP-卡巴他赛耐受性良好,在晚期实体瘤中显示出持久的抗肿瘤活性,且骨髓毒性较传统卡巴他赛报道有所降低。

研究设计与样本

  • 这是一项1/2期首次人体试验,评估DEP-卡巴他赛在晚期实体瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性。
  • 成人患者每3周接受一次DEP-卡巴他赛;1期主要目标为确定MTD和DLT,次要目标包括安全性、RP2D、药代动力学和初步疗效。

主要发现

  • 在MTD和RP2D为20 mg/m2卡巴他赛时未观察到DLT。
  • 最常见的归因于DEP-卡巴他赛的治疗中出现的不良事件为乏力、周围神经病变、恶心、贫血、中性粒细胞减少、腹泻和呕吐。
  • 在75例2期患者中,3/4级中性粒细胞减少发生率为22.7%,发热性中性粒细胞减少为1.3%。
  • 在RECIST可评估的2期患者中,客观缓解率(ORR)为20%(9/45可测量),疾病控制率(DCR)为70.6%(36/51)。
  • 按肿瘤类型,mCRPC、PROC、EGC和1例胸腺癌患者的ORR分别为16.7%、17.6%、30.0%和100%。

关键数值与推荐

  • MTD和RP2D为20 mg/m2卡巴他赛,未观察到DLT。
  • 2期可评估患者ORR为20%(9/45),DCR为70.6%(36/51)。
  • 3/4级中性粒细胞减少发生率为22.7%,发热性中性粒细胞减少为1.3%。
  • mCRPC、PROC、EGC和胸腺癌患者的ORR分别为16.7%、17.6%、30.0%和100%。
  • 中位PFS为3.8个月,中位OS为9.0个月。

临床怎么用

  • DEP-卡巴他赛以20 mg/m2每3周给药在晚期实体瘤中显示出可管理的安全性和初步抗肿瘤活性。
  • 在mCRPC、PROC和EGC中观察到客观缓解和疾病控制,支持进一步评估。
  • 骨髓毒性尤其是3/4级中性粒细胞减少和发热性中性粒细胞减少发生率较低,可能有利于需要长期治疗的患者。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase 1/2 trial evaluated safety, tolerability, pharmacokinetics, and antitumour activity of DEP-cabazitaxel (CTX-SPL9111), a dendrimer-cabazitaxel nanoparticle, in solid tumours. METHODS: Adult patients received DEP-cabazitaxel once every 3 weeks. The primary phase 1 objective was to establish the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary objectives were to assess safety and tolerability, define the recommended phase 2 dose (RP2D), and evaluate pharmacokinetics and preliminary efficacy. RESULTS: Eighty-nine patients enrolled; most phase 2 patients had metastatic castrate-resistant prostate cancer (mCRPC; n = 25), platinum-resistant ovarian cancer (PROC; n = 22), or esophago-gastric cancer (EGC; n = 15). No DLTs were observed at the MTD and RP2D of 20 mg/m2 cabazitaxel. Most common treatment-emergent adverse events attributed to DEP-cabazitaxel were fatigue, peripheral neuropathy, nausea, anaemia, neutropenia, diarrhoea, and vomiting. In 75 phase 2 patients, Grade 3/4 neutropenia occurred in 22.7% and febrile neutropenia in 1.3%. In RECIST-evaluable phase 2 patients, the objective response rate (ORR) was 20% (9/45 measurable) and disease control rate (DCR) was 70.6% (36/51). By tumor type, ORRs were 16.7%, 17.6%, 30.0%, and 100% for mCRPC, PROC, EGC, and a thymic cancer patient, respectively. In evaluable phase 2 patients, 90.5% with mCRPC had PSA reductions (52.4% by >50%) and 86.7% had stable or improved bone metastases, and 75% with PROC had reduced CA‑125 or CEA. Median progression-free and overall survival were 3.8 and 9.0 months, respectively. CONCLUSION: DEP-cabazitaxel was well tolerated and showed durable antitumour activity across advanced solid tumours, with reduced bone marrow toxicity compared to that reported for conventional cabazitaxel.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jones RH, Pinato DJ, Forster MD, et al. Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours. Eur J Cancer. 2026. PMID: 42208277. doi:10.1016/j.ejca.2026.116821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。